453 related articles for article (PubMed ID: 26692764)
1. Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer.
Inoue K; Fry EA
Genet Epigenet; 2015; 7():19-32. PubMed ID: 26692764
[TBL] [Abstract][Full Text] [Related]
2. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.
Olsson E; Honeth G; Bendahl PO; Saal LH; Gruvberger-Saal S; Ringnér M; Vallon-Christersson J; Jönsson G; Holm K; Lövgren K; Fernö M; Grabau D; Borg A; Hegardt C
BMC Cancer; 2011 Sep; 11():418. PubMed ID: 21957977
[TBL] [Abstract][Full Text] [Related]
3. Computational Inferences of the Functions of Alternative/Noncanonical Splice Isoforms Specific to HER2+/ER-/PR- Breast Cancers, a Chromosome 17 C-HPP Study.
Menon R; Panwar B; Eksi R; Kleer C; Guan Y; Omenn GS
J Proteome Res; 2015 Sep; 14(9):3519-29. PubMed ID: 26147891
[TBL] [Abstract][Full Text] [Related]
4. TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44.
Chen Q; Gu M; Cai ZK; Zhao H; Sun SC; Liu C; Zhan M; Chen YB; Wang Z
Cell Mol Life Sci; 2021 Feb; 78(3):949-962. PubMed ID: 32440711
[TBL] [Abstract][Full Text] [Related]
5. CD44 splice isoform switching determines breast cancer stem cell state.
Zhang H; Brown RL; Wei Y; Zhao P; Liu S; Liu X; Deng Y; Hu X; Zhang J; Gao XD; Kang Y; Mercurio AM; Goel HL; Cheng C
Genes Dev; 2019 Feb; 33(3-4):166-179. PubMed ID: 30692202
[TBL] [Abstract][Full Text] [Related]
6. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer.
Friedrichs K; Franke F; Lisboa BW; Kügler G; Gille I; Terpe HJ; Hölzel F; Maass H; Günthert U
Cancer Res; 1995 Nov; 55(22):5424-33. PubMed ID: 7585612
[TBL] [Abstract][Full Text] [Related]
7. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.
Gaiteiro C; Soares J; Relvas-Santos M; Peixoto A; Ferreira D; Paulo P; Brandão A; Fernandes E; Azevedo R; Palmeira C; Freitas R; Miranda A; Osório H; Prieto J; Lima L; Silva AMN; Santos LL; Ferreira JA
Theranostics; 2022; 12(7):3150-3177. PubMed ID: 35547758
[No Abstract] [Full Text] [Related]
8. Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.
Inoue K; Fry EA
Int J Cancer; 2016 Jul; 139(1):33-41. PubMed ID: 26802432
[TBL] [Abstract][Full Text] [Related]
9. Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.
Liu Y; Li M; Fang Z; Gao S; Cheng W; Duan Y; Wang X; Feng J; Yu T; Zhang J; Wang T; Hu A; Zhang H; Rong Z; Shakila SS; Shang Y; Kong F; Liu J; Li Y; Ma F
Cancer Immunol Immunother; 2024 May; 73(7):117. PubMed ID: 38713229
[TBL] [Abstract][Full Text] [Related]
10. CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3/STAT3 signaling pathway.
Liu YN; Tsai MF; Wu SG; Chang TH; Shih JY
Life Sci; 2024 Jan; 336():122345. PubMed ID: 38092140
[TBL] [Abstract][Full Text] [Related]
11. Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer.
Castro-Guijarro AC; Sanchez AM; Flamini MI
Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686651
[TBL] [Abstract][Full Text] [Related]
12. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
[TBL] [Abstract][Full Text] [Related]
13. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
[TBL] [Abstract][Full Text] [Related]
15. CD44: structure, function, and association with the malignant process.
Naor D; Sionov RV; Ish-Shalom D
Adv Cancer Res; 1997; 71():241-319. PubMed ID: 9111868
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 7 receptor alpha Thr244Ile genetic polymorphism is associated with susceptibility and prognostic markers in breast cancer subgroups.
Vitiello GAF; Losi Guembarovski R; Amarante MK; Ceribelli JR; Carmelo ECB; Watanabe MAE
Cytokine; 2018 Mar; 103():121-126. PubMed ID: 28964592
[TBL] [Abstract][Full Text] [Related]
17. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
18. A cell-to-patient machine learning transfer approach uncovers novel basal-like breast cancer prognostic markers amongst alternative splice variants.
Villemin JP; Lorenzi C; Cabrillac MS; Oldfield A; Ritchie W; Luco RF
BMC Biol; 2021 Apr; 19(1):70. PubMed ID: 33845831
[TBL] [Abstract][Full Text] [Related]
19. CD44 and its implication in neoplastic diseases.
Xu Y; Bai Z; Lan T; Fu C; Cheng P
MedComm (2020); 2024 Jun; 5(6):e554. PubMed ID: 38783892
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal splice isoform of CD44 (CD44s) promotes EMT/invasion and imparts stem-like properties to ovarian cancer cells.
Bhattacharya R; Mitra T; Ray Chaudhuri S; Roy SS
J Cell Biochem; 2018 Apr; 119(4):3373-3383. PubMed ID: 29130517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
